Skip to main content
Figure 4 | Molecular Medicine

Figure 4

From: Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Figure 4

(A) Age-matched male NOD/SCID mice were injected subcutaneously with UM-UC-6 cells and were treated with dacomitinib (Dac) 6 mg/kg or vehicle (0.05 N Na lactate buffer, pH 4.0; PO once daily), starting 1 d (early) or 1 wk (late) after injection. Xenografts weights were lower in Dac versus vehicle (p < 0.001) (B) Age-matched male NOD/SCID mice were subcutaneously injected with UM-UC-9 cells and were treated with Dac 6mg/kg or lapatinib (Lap) 50mg/kg or vehicle PO once daily, starting 1 d or 1 wk after injection. Xenografts weights were lower in Dac versus vehicle (p < 0.001). Dac resulted in significantly lower tumor weights versus Lap (p = 0.0052). (C) UM-UC-6 xenografts were established in age-matched NOD/SCID mice, which were treated a week after cell injection. Tumor weights were significantly lower with Dac, and gemcitabine-cisplatin (GC) + Dac versus no treatment (No Tx) (p < 0.0001) or versus GC (p < 0.0001). (D) The same experiment was performed in UM-UC-9 xenografts. Tumor weights were significantly lower with Dac (p = 0.002; 6-x reduction) or GC (p = 0.0006; 7-x reduction) versus no treatment (No Tx). GC + Dac-treated xenografts had significantly lower weights versus GC (p = 0.005), Dac (p = 0.06) or no treatment (p < 0.0001; 17-fold reduction).

Back to article page